Adapted from a press release:
Elanco Animal Health Incorporated executives agreed to acquire Kindred Biosciences, a biopharmaceutical company focused on developing novel pet therapeutics based on validated human targets. The acquisition further accelerates Elanco’s expansion in the pet health market, particularly advancing Elanco’s presence in the dermatology category.